At ASM Microbe 2025, a cross-sectional study highlights Burkholderia cepacia dominance, widespread antibiotic resistance, and key risk factors, including invasive device use and patient demographics.

At the ASM Microbe conference, Mike Bromley, PhD, offers some insights on the importance of a One Health approach addressing the growing antifungal resistance to azoles and Aspergillus fumigatus because of the connection between crop spraying and the rise of resistance.

At ASM Microbe 2025, researchers underscore the role of NAAT in outpatient CDI diagnosis and raise concerns over PPI-related risk in older, healthcare-associated cases.

Study presented at ASM Microbe 2025 questions the clinical value of adding enzyme immunoassays to PCR-based CDI diagnostics amid sensitivity concerns.

Presented at ASM Microbe 2025, a bioinformatics study highlights nine human miRNAs capable of binding and potentially inhibiting both hepatitis C and bovine viral diarrhea viruses.

Gilead’s Yeztugo, a long-acting HIV capsid inhibitor, shows 96 to 100% efficacy in phase 3 trials and aims to expand access worldwide through regulatory filings and support programs.

A ValuePenguin poll of more than 2000 adults highlights partisan divides, persistent myths, and concerns over vaccine access, with 41% fearing skepticism could hinder immunization efforts.

Part 3 with Robert Bransfield, MD, explores treatment-resistant mental health issues linked to infection history and diverse progression patterns.

Data from the 2023 Centers for Disease Control and Prevention surveillance report highlight key differences in death rates across states and populations, informing targeted public health efforts.

After initially closing its viral hepatitis and sexually transmitted disease laboratories, the CDC rescinds staff terminations, preserving vital disease surveillance and outbreak response capabilities.

Study underscores value of obtaining sputum culture prior to initiating antibiotics, for greater detection of pathogens without opportunistic bacteria of uncertain clinical relevance.

In our latest podcast, Tim Gauthier, PharmD, BCPS, BCIDP, discusses all things pathogens and antibiotics. He also details the opportunities presented for antimicrobial stewardship when it combines diagnostics and treatment duration.

Evaluating safety and efficacy against symptomatic, virologically confirmed dengue in children and adolescents.

In an early release of his letter for the Summer issue, Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the recent changes to the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), and where professional societies must step in and lead with research data and clinical guidance in the absence of experienced committee members.

Successful HCV treatment with DAAs was associated with reduced risks of CKD, stroke, major adverse cardiac events, and neurocognitive disorders.

Jatin Vyas, PhD, MD, offers some insights into the economics of development, the biology of fungal species, and the difficulties behind creating new antifungal molecules.

This week, the FDA expanded Moderna’s RSV vaccine to younger at-risk adults, Merck’s Enflonsia received approval to protect infants from RSV, HHS Secretary RFK Jr replaced the CDC’s ACIP, and more.

The antiviral, glecaprevir/pibrentasvir (Mavyet), is the first and only oral 8-week pangenotypic treatment approved for people with acute or chronic hepatitis C. The approval supports global clinical guidelines to advance testing and treatment of HCV regardless of chronicity and supports public health goals for disease elimination.

Innoviva and GARDP's breakthrough treatment could become the first new gonorrhea antibiotic in decades amid rising antimicrobial resistance.

The federal agency approved the company’s mRNA-1345 (mRESVIA) vaccine for people who are between the ages of 18 to 59 years.

Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.

Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings.

The replacement of all 17 ACIP members sparks concern among medical experts and prompts calls for Senate investigation.

New modeling estimates up to 360,000 symptomatic cases annually, 10 to 18 times higher than reported, with CDC experts calling for expanded testing, reporting, and clinical awareness.

Enflonsia, a single-dose, long-acting antibody, has been FDA approved to significantly reduce RSV infections and hospitalizations in infants, providing new hope for protecting vulnerable babies during RSV season.